vs

Side-by-side financial comparison of Royalty Pharma plc (RPRX) and TKO Group Holdings (TKO). Click either name above to swap in a different company.

TKO Group Holdings is the larger business by last-quarter revenue ($1.0B vs $622.0M, roughly 1.7× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs -0.2%, a 34.7% gap on every dollar of revenue. On growth, TKO Group Holdings posted the faster year-over-year revenue change (61.6% vs 4.8%). Over the past eight quarters, TKO Group Holdings's revenue compounded faster (28.4% CAGR vs 4.6%).

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

TKO Group Holdings, Inc. (TKO) is an American sports and sports entertainment company. Established on September 12, 2023, the public company was formed by a merger between Endeavor subsidiary Zuffa—the parent company of the Ultimate Fighting Championship (UFC), a mixed martial arts promotion—and the professional wrestling promotion World Wrestling Entertainment (WWE).

RPRX vs TKO — Head-to-Head

Bigger by revenue
TKO
TKO
1.7× larger
TKO
$1.0B
$622.0M
RPRX
Growing faster (revenue YoY)
TKO
TKO
+56.9% gap
TKO
61.6%
4.8%
RPRX
Higher net margin
RPRX
RPRX
34.7% more per $
RPRX
34.4%
-0.2%
TKO
Faster 2-yr revenue CAGR
TKO
TKO
Annualised
TKO
28.4%
4.6%
RPRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RPRX
RPRX
TKO
TKO
Revenue
$622.0M
$1.0B
Net Profit
$214.2M
$-2.4M
Gross Margin
Operating Margin
62.4%
5.5%
Net Margin
34.4%
-0.2%
Revenue YoY
4.8%
61.6%
Net Profit YoY
2.9%
-107.7%
EPS (diluted)
$0.49
$-0.07

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RPRX
RPRX
TKO
TKO
Q4 25
$622.0M
$1.0B
Q3 25
$609.3M
$1.1B
Q2 25
$578.7M
$1.3B
Q1 25
$568.2M
$1.3B
Q4 24
$593.6M
$642.2M
Q3 24
$564.7M
$681.3M
Q2 24
$537.3M
$851.2M
Q1 24
$568.0M
$629.7M
Net Profit
RPRX
RPRX
TKO
TKO
Q4 25
$214.2M
$-2.4M
Q3 25
$288.2M
$41.0M
Q2 25
$30.2M
$98.4M
Q1 25
$238.3M
$58.4M
Q4 24
$208.2M
$31.0M
Q3 24
$544.0M
$23.1M
Q2 24
$102.0M
$59.1M
Q1 24
$4.8M
$-103.8M
Operating Margin
RPRX
RPRX
TKO
TKO
Q4 25
62.4%
5.5%
Q3 25
70.1%
15.4%
Q2 25
36.3%
28.1%
Q1 25
94.0%
18.7%
Q4 24
60.9%
15.9%
Q3 24
20.0%
Q2 24
50.2%
30.0%
Q1 24
-13.0%
-33.4%
Net Margin
RPRX
RPRX
TKO
TKO
Q4 25
34.4%
-0.2%
Q3 25
47.3%
3.7%
Q2 25
5.2%
7.5%
Q1 25
41.9%
4.6%
Q4 24
35.1%
4.8%
Q3 24
96.3%
3.4%
Q2 24
19.0%
6.9%
Q1 24
0.8%
-16.5%
EPS (diluted)
RPRX
RPRX
TKO
TKO
Q4 25
$0.49
$-0.07
Q3 25
$0.67
$0.47
Q2 25
$0.07
$1.17
Q1 25
$0.55
$0.69
Q4 24
$0.46
$0.28
Q3 24
$1.21
$0.28
Q2 24
$0.23
$0.72
Q1 24
$0.01
$-1.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RPRX
RPRX
TKO
TKO
Cash + ST InvestmentsLiquidity on hand
$618.7M
$831.1M
Total DebtLower is stronger
$9.0B
$3.8B
Stockholders' EquityBook value
$9.7B
$3.7B
Total Assets
$19.6B
$15.5B
Debt / EquityLower = less leverage
0.92×
1.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RPRX
RPRX
TKO
TKO
Q4 25
$618.7M
$831.1M
Q3 25
$938.9M
$861.4M
Q2 25
$631.9M
$535.1M
Q1 25
$1.1B
$470.9M
Q4 24
$929.0M
$525.6M
Q3 24
$950.1M
$457.4M
Q2 24
$1.8B
$277.5M
Q1 24
$843.0M
$245.8M
Total Debt
RPRX
RPRX
TKO
TKO
Q4 25
$9.0B
$3.8B
Q3 25
$8.9B
$3.7B
Q2 25
$8.0B
$2.7B
Q1 25
$7.6B
$2.8B
Q4 24
$7.6B
$2.8B
Q3 24
$7.6B
$2.7B
Q2 24
$7.6B
$2.7B
Q1 24
$6.1B
$2.7B
Stockholders' Equity
RPRX
RPRX
TKO
TKO
Q4 25
$9.7B
$3.7B
Q3 25
$9.6B
$3.8B
Q2 25
$9.5B
$4.3B
Q1 25
$9.8B
$4.2B
Q4 24
$10.3B
$4.1B
Q3 24
$10.3B
$4.0B
Q2 24
$9.8B
$4.0B
Q1 24
$9.9B
$4.0B
Total Assets
RPRX
RPRX
TKO
TKO
Q4 25
$19.6B
$15.5B
Q3 25
$19.3B
$15.5B
Q2 25
$18.3B
$15.3B
Q1 25
$17.6B
$15.0B
Q4 24
$18.2B
$12.7B
Q3 24
$18.0B
$12.8B
Q2 24
$17.7B
$12.7B
Q1 24
$16.1B
$12.7B
Debt / Equity
RPRX
RPRX
TKO
TKO
Q4 25
0.92×
1.01×
Q3 25
0.93×
0.98×
Q2 25
0.84×
0.64×
Q1 25
0.78×
0.66×
Q4 24
0.74×
0.67×
Q3 24
0.74×
0.67×
Q2 24
0.78×
0.68×
Q1 24
0.62×
0.68×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RPRX
RPRX
TKO
TKO
Operating Cash FlowLast quarter
$827.1M
$309.9M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
3.86×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RPRX
RPRX
TKO
TKO
Q4 25
$827.1M
$309.9M
Q3 25
$702.6M
$416.8M
Q2 25
$364.0M
$396.2M
Q1 25
$596.1M
$162.8M
Q4 24
$742.5M
$56.8M
Q3 24
$703.6M
$236.5M
Q2 24
$658.2M
$230.7M
Q1 24
$664.6M
$59.3M
Cash Conversion
RPRX
RPRX
TKO
TKO
Q4 25
3.86×
Q3 25
2.44×
10.16×
Q2 25
12.06×
4.03×
Q1 25
2.50×
2.79×
Q4 24
3.57×
1.83×
Q3 24
1.29×
10.22×
Q2 24
6.45×
3.90×
Q1 24
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

TKO
TKO

World Wrestling Entertainment Segment$359.6M35%
IMG Segment$247.6M24%
Media Rights Production And Content$222.6M21%
Partnerships And Marketing$93.3M9%
Live Events And Hospitality$72.2M7%
Other$29.4M3%
Consumer Products Licensing And Other$13.2M1%

Related Comparisons